Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

4236 - MicroRNA-31 overexpression is able to predict pathological response and outcome in locally advanced rectal cancer


08 Oct 2016


Poster Display


Cristina Carames


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


C. Carames1, I. Cristobal2, P. Minguez2, V. Moreno3, H. Callata-Carhuapoma1, A. Leon3, J.I. Martin3, M. Domine3, R. Hernandez3, M. Pedregal3, I. Martinez3, I. Moreno3, A. Correa3, F. Rojo4, J.M. García-Foncillas López3

Author affiliations

  • 1 Oncohealth Institute, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 2 Translational Oncology-oncohealth Institute, University Hospital "Fundacion Jimenez Diaz", Madrid/ES
  • 3 Oncohealth Institute, University Hospital "Fundacion Jimenez Diaz", Madrid/ES
  • 4 Pathology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES


Abstract 4236


The treatment of choice for locally advanced rectal cancer is preoperative chemoradiotherapy (CRT). Despite around half of patients do not respond, suffer unnecessary toxicities and surgery delays, there are no biomarkers to guide preoperative CRT outcome. MicroRNA-31 (miR-31) has been related to acquisition of 5-fluorouracil resistance in rectal cancer however its potential predictive value of response to preoperative CRT in locally advanced rectal cancer remains unknown.


Eight-two patients diagnosed with locally advanced rectal cancer who were preoperatively treated with 5-fluorouracil based CRT were selected for this study. The miR-31 expression was quantified in formalin-fixed paraffin-embedded biopsies from this cohort previous to CRT therapy administration and the results obtained were correlated with clinical and molecular characteristics, pathological response and outcome.


Overexpression of miR-31 was found in 34.2% of the cases. Its overexpression significantly predicted poor pathological response (p = 0.018) and worse overall survival (OS) (p = 0.008). Multivariate analysis confirmed the clinical significance of miR-31 in determining pathological response to neoadjuvant CRT as well as OS.


miR-31 quantification emerges as a novel valuable clinical tool to predict both pathological response and outcome in locally advanced rectal cancer patients.

Clinical trial identification

Legal entity responsible for the study



Fundación Jimenez Diaz


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings